News | Biogen

April 24, 2024

BIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024

March 31, 2024

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA

March 22, 2024

Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application

March 12, 2024

Biogen to Participate in the Stifel 2024 Virtual CNS Days

March 7, 2024

Eisai to Host Annual Information Meeting with Update on LEQEMBI® (lecanemab-irmb)

March 6, 2024

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

March 4, 2024

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

February 26, 2024

Biogen to Participate in the TD Cowen 44th Annual Health Care Conference

February 23, 2024

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

February 13, 2024

Biogen Reports Fourth Quarter and Full Year 2023 Results

February 12, 2024

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

January 31, 2024

Biogen to Realign Resources for Alzheimer's Disease Franchise

January 12, 2024

BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS FEBRUARY 13, 2024

January 11, 2024

Update on Marketing Authorization Application for Lecanemab in the European Union

January 9, 2024

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China

December 19, 2023

Biogen to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

December 15, 2023

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

December 14, 2023

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

December 12, 2023

“LEQEMBI® Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20

November 16, 2023

Biogen to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 8, 2023

Biogen Reports Third Quarter 2023 Results

November 6, 2023

Biogen Appoints Monish Patolawala to its Board of Directors

October 31, 2023

JAMA Neurology Publishes Data on Biogen’s Investigational Antisense Oligonucleotide Targeting Tau

October 25, 2023

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzhe

October 25, 2023

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

October 19, 2023

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

October 11, 2023

BIOGEN TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS NOVEMBER 8, 2023

September 29, 2023

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

September 26, 2023

Biogen Completes Acquisition of Reata Pharmaceuticals

September 25, 2023

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

September 21, 2023

STATEMENT: BIOGEN PROVIDES UPDATE ON THE ACQUISITION OF REATA PHARMACEUTICALS

September 6, 2023

Biogen Appoints Jane Grogan as Head of Research

August 30, 2023

Biogen to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 4, 2023

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

July 28, 2023

Biogen to Acquire Reata Pharmaceuticals

July 25, 2023

Biogen Reports Second Quarter 2023 Results

July 19, 2023

Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023

July 10, 2023

BIOGEN TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS JULY 25, 2023

July 6, 2023

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

June 30, 2023

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

June 26, 2023

Biogen Announces 2023 Annual Shareholder Meeting Preliminary Results

June 12, 2023

Biogen Announces Changes to Its Board of Directors

June 9, 2023

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

June 9, 2023

Biogen Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental Biologics License Application for the Potential Traditional Approval of LEQEMBI in Early Alzheimer’s Disease

June 7, 2023

EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN SOUTH KOREA

June 6, 2023

Biogen Withdrawal from the Jefferies Healthcare Conference

June 5, 2023

Statement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program

June 1, 2023

Biogen Announces Webcast of Annual Meeting of Stockholders

May 23, 2023

Biogen to Participate in the Jefferies Healthcare Conference

May 21, 2023

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN GREAT BRITAIN

May 15, 2023

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

May 3, 2023

Biogen Files Form 8-K

May 1, 2023

BIOGEN PUBLISHES 2022 ESG REPORT

April 28, 2023

Biogen Announces Publication of BIIB080 Phase 1b Data in Nature Medicine

April 25, 2023

Biogen Reports First Quarter 2023 Results

April 25, 2023

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

April 12, 2023

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

April 11, 2023

BIOGEN TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS APRIL 25, 2023

April 4, 2023

Biogen Appoints Adam Keeney as Head of Corporate Development

March 30, 2023

Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

March 30, 2023

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

March 29, 2023

New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease

March 22, 2023

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

March 17, 2023

Biogen to Participate in the Stifel 2023 CNS Days

March 16, 2023

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

March 14, 2023

Biogen Appoints Chuck Triano as Head of Investor Relations

March 13, 2023

A Statement from Biogen on Access to LEQEMBI™

March 8, 2023

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

March 8, 2023

Biogen and Sage Therapeutics Share Update on FDA Advisory Committee for Zuranolone

March 5, 2023

FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

February 27, 2023

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

February 20, 2023

Biogen to Participate in the Cowen 43rd Annual Health Care Conference

February 15, 2023

Biogen Reports Fourth Quarter and Full Year 2022 Results

February 6, 2023

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

January 29, 2023

Lecanemab Receives Priority Review Status in Japan

January 26, 2023

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

January 23, 2023

Biogen Shares Update on FDA Advisory Committee Meeting for Tofersen

January 18, 2023

BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS FEBRUARY 15, 2023

January 15, 2023

EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN JAPAN

January 10, 2023

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN EUROPE

January 6, 2023

Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

January 6, 2023

A statement from Biogen on LEQEMBI™ pricing

January 6, 2023

FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

January 5, 2023

Biogen Names Priya Singhal as Executive Vice President, Head of Development

January 4, 2023

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

December 29, 2022

Corporate Statement on Report by the Staffs of the Committee on Oversight and Reform and Committee on Energy and Commerce

December 22, 2022

Eisai Initiates BLA Submission of Data for Lecanemab in China

December 22, 2022

Biogen to Participate in the 41st Annual J.P. Morgan Healthcare Conference

December 19, 2022

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

December 9, 2022

FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)

December 6, 2022

Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

December 5, 2022

European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS

November 29, 2022

Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference

November 29, 2022

Eleven Experts From Leading Medical Institutions And Eight Experts From Eisai* Publish Full Results Of Lecanemab Phase 3 Confirmatory Clarity Ad Study For Early Alzheimer’s Disease In The New England Journal Of Medicine

November 22, 2022

Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone

November 17, 2022

Biogen to Participate in the 5th Annual Evercore ISI HealthCONx Conference

November 10, 2022

Biogen Names Christopher Viehbacher President and Chief Executive Officer

October 26, 2022

Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS

October 26, 2022

New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS

October 25, 2022

Biogen Reports Third Quarter 2022 Results

October 17, 2022

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

October 17, 2022

Biogen and Sage Therapeutics Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

October 11, 2022

BIOGEN TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS OCTOBER 25, 2022

October 10, 2022

Biogen Announces First Patient Dosed in Pivotal Study of Litifilimab in Cutaneous Lupus Erythematosus, an Autoimmune Disease Affecting Skin

October 3, 2022

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

September 30, 2022

Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)

September 27, 2022

LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE

September 26, 2022

Statement: Biogen Statement On Qui Tam Settlement

September 21, 2022

The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS

September 20, 2022

STATEMENT: BIOGEN COMPLETES CORPORATE REAL ESTATE TRANSACTION TO ALIGN ITS CAMBRIDGE OFFICE SPACE FOOTPRINT WITH NEW WORKING ENVIRONMENT

September 19, 2022

Biogen and Sage Therapeutics Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone

September 7, 2022

The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus

August 31, 2022

Biogen to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

August 31, 2022

Statement on Alzheimer’s & Dementia® Journal Publication about Association between Reduction of Amyloid Beta and Slowing of Cognitive and Functional Decline in Alzheimer’s Disease

August 3, 2022

EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022

July 28, 2022

The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus

July 26, 2022

FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

July 20, 2022

Biogen Reports Second Quarter 2022 Results

July 6, 2022

Biogen to Report Second Quarter 2022 Financial Results July 20, 2022

July 5, 2022

The U.S. FDA Accepts and Grants Priority Review for EISAI’s Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

June 22, 2022

Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform

June 21, 2022

European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)

June 15, 2022

Biogen Appreciation Statement for Retiring Board Members Nancy Leaming and Brian Posner

June 15, 2022

New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)

June 14, 2022

The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities

June 8, 2022

Biogen Withdrawal from the Jefferies Healthcare Conference

June 6, 2022

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

June 3, 2022

Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)

June 3, 2022

New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS

June 2, 2022

Biogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States

June 1, 2022

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

May 31, 2022

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

May 26, 2022

Biogen to Participate in the Jefferies Healthcare Conference

May 9, 2022

EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY

May 5, 2022

Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis

May 3, 2022

Biogen Reports First Quarter 2022 Results

May 2, 2022

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

April 29, 2022

Biogen Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in US

April 28, 2022

Biogen To Offer Continuity of Care Plan for U.S. Patients Currently Treated with ADUHELM® (aducanumab-avwa)

April 22, 2022

Update on Regulatory Submission for Aducanumab in the European Union

April 20, 2022

Biogen Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics for $2.3 Billion

April 7, 2022

Biogen’s Statement on the Final National Coverage Determination for Amyloid-Beta Targeting Therapies for the Treatment of Alzheimer’s Disease

April 5, 2022

Biogen to Report First Quarter 2022 Financial Results May 3, 2022

April 4, 2022

New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression

March 30, 2022

Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA

March 28, 2022

Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

March 21, 2022

Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting

March 18, 2022

The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence White Paper

March 17, 2022

Biogen to Participate in the Stifel 2022 CNS Days

March 16, 2022

Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease

March 16, 2022

Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years

March 14, 2022

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments

March 14, 2022

Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference

March 11, 2022

Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)

March 4, 2022

EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB

February 18, 2022

Biogen to Present at the Cowen 42nd Annual Health Care Conference

February 16, 2022

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD

February 10, 2022

Biogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed National Coverage Determination (NCD) for Anti-Amyloid Treatments in Alzheimer’s Disease

February 7, 2022

Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis

February 3, 2022

Biogen Reports Fourth Quarter and Full Year 2021 Results

February 1, 2022

Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody

January 31, 2022

Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors

January 27, 2022

Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

January 27, 2022

Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®

January 19, 2022

Biogen to Report Fourth Quarter and Full Year 2021 Financial Results February 3, 2022

January 11, 2022

Biogen’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

January 10, 2022

Biogen to Host Analyst Q&A Call

January 4, 2022

Biogen to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

December 23, 2021

Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation

December 22, 2021

Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review

December 20, 2021

Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease

December 17, 2021

Update on Regulatory Submission for Aducanumab in the European Union

December 16, 2021

Update on the Phase 4 Confirmatory Study of ADUHELM®

December 14, 2021

Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience

December 1, 2021

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

November 22, 2021

Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

November 17, 2021

Update on Regulatory Review of Aducanumab in the European Union

November 16, 2021

The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis

November 15, 2021

Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development

November 15, 2021

Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year

November 11, 2021

New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease

November 11, 2021

Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 11, 2021

Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2B Study at Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 10, 2021

Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2B Study Core and Open-Label Extension Across Five Years at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

November 3, 2021

Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

November 2, 2021

A Letter from Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It’s Time for Companies to Act Like the Climate Crisis is a Health Crisis

October 20, 2021

Biogen Reports Third Quarter 2021 Results

October 19, 2021

Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022

October 17, 2021

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

October 14, 2021

Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting

October 13, 2021

New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

October 13, 2021

New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

October 6, 2021

Biogen to Report Third Quarter 2021 Financial Results October 20, 2021

October 4, 2021

Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress

September 27, 2021

Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway

September 23, 2021

Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative

September 21, 2021

Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience

September 20, 2021

FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)

September 17, 2021

CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis

September 16, 2021

Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy

September 15, 2021

Biogen Announces Agenda for Virtual Investor Day R&D Day on September 21, 2021

September 15, 2021

Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)

September 1, 2021

Biogen to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

August 2, 2021

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

July 29, 2021

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)

July 29, 2021

Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021

July 26, 2021

Biogen and Ionis report positive topline clinical data on investigational Alzheimer’s disease treatment at AAIC

July 26, 2021

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

July 23, 2021

Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference

July 22, 2021

An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.

July 22, 2021

Biogen Reports Second Quarter 2021 Results

July 12, 2021

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

July 8, 2021

Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease

July 8, 2021

Biogen to Report Second Quarter 2021 Financial Results July 22, 2021

July 8, 2021

FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials

June 25, 2021

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™

June 23, 2021

EISAI and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation for LECANEMAB (BAN2401), an Anti-Amyloid Beta Protofibril Antibody for the Treatment of Alzheimer's Disease

June 23, 2021

Biogen and Eisai Update for the Alzheimer’s Disease Community

June 22, 2021

Biogen to Participate in SVB Leerink’s 3rd Annual CNS Forum

June 17, 2021

Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

June 16, 2021

Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease

June 15, 2021

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

June 14, 2021

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia

June 10, 2021

Biogen Announces Investor Day on September 21, 2021

June 10, 2021

New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy

June 7, 2021

A Letter from Biogen’s CEO on ADUHELM

June 7, 2021

Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™

June 7, 2021

FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

June 2, 2021

Biogen Statement about Director and Chair of the Compensation and Management Development Committee Robert W. Pangia

June 1, 2021

Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)

May 25, 2021

Biogen Announces Webcast of Annual Meeting of Stockholders

May 21, 2021

Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform

May 20, 2021

Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland

May 14, 2021

Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP

May 13, 2021

Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research

May 12, 2021

Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data

May 10, 2021

Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders

April 28, 2021

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

April 28, 2021

Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics

April 22, 2021

Biogen Reports First Quarter 2021 Results

April 19, 2021

18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy

April 19, 2021

Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

April 16, 2021

New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

April 15, 2021

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

April 14, 2021

Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021

April 12, 2021

Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint

April 9, 2021

Biogen Announces Two New Nominees for Election to Board of Directors

April 8, 2021

Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis

April 7, 2021

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis

March 4, 2021

Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina

February 24, 2021

Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program

February 11, 2021

Biogen Announces the Expiration Date Results of Its Cash Tender Offer

February 11, 2021

Biogen Announces the Expiration Date Results of Its Private Exchange Offer

February 11, 2021

Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups

February 10, 2021

Biogen Announces the Pricing Terms of its Cash Tender Offer

February 10, 2021

Biogen Announces the Pricing Terms of Its Private Exchange Offer

February 4, 2021

Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only

February 4, 2021

Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors

February 3, 2021

Biogen Reports Fourth Quarter and Full Year 2020 Results

February 1, 2021

Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis

January 29, 2021

Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab

January 13, 2021

Biogen to Report Fourth Quarter and Full Year 2020 Financial Results February 3, 2021

January 13, 2021

A statement about Biogen Political Action Committee

January 11, 2021

Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone

January 8, 2021

Biogen to Participate in Webinar with Alzheimer's Disease International on January 14, 2021

January 8, 2021

Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)

January 4, 2021

Biogen to Present at the 39th Annual J.P. Morgan Healthcare Conference

December 21, 2020

The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis

December 9, 2020

Biogen Files New Drug Application for Aducanumab in Japan

November 27, 2020

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

November 18, 2020

Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)

November 16, 2020

Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership

November 6, 2020

Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease

November 3, 2020

Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020

November 3, 2020

Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting

October 30, 2020

European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease

October 21, 2020

Biogen Reports Q3 2020 Results

October 7, 2020

Biogen to Report Third Quarter 2020 Financial Results October 21, 2020

October 6, 2020

Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)

September 29, 2020

Statement about the FDA advisory committee on aducanumab

September 29, 2020

Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab

September 22, 2020

Biogen to Webcast Prerecorded Encore Aducanumab Presentation and Live Q&A from AAN 2020 Science Highlights on September 23, 2020

September 14, 2020

Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health

September 11, 2020

New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio

September 8, 2020

New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS

September 2, 2020

Biogen to Participate in the Morgan Stanley Virtual Global Healthcare Conference

August 27, 2020

Biogen to Webcast Prerecorded Encore Aducanumab Presentation from 61st Annual Meeting of the Japanese Society of Neurology on August 31, 2020

August 7, 2020

FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review

August 6, 2020

Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases

July 24, 2020

Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease

July 22, 2020

Biogen Reports Q2 2020 Revenues of $3.7 Billion

July 21, 2020

Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer

July 21, 2020

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)

July 13, 2020

Initiation of New Phase III Clinical Study (AHEAD 3-45) of BAN2401 Preclinical (Asymptomatic) Alzheimer’s Disease

July 8, 2020

The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS

July 8, 2020

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease

July 7, 2020

Biogen to Report Second Quarter 2020 Financial Results July 22, 2020

June 16, 2020

Biogen to Participate in SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum

June 10, 2020

New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment

June 4, 2020

Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020

June 2, 2020

Biogen Statement about Director Lynn Schenk

May 28, 2020

Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science

May 19, 2020

New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS

May 18, 2020

New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients

May 15, 2020

Biogen to Webcast Prerecorded Encore Aducanumab Presentation from AAN Science Highlights Virtual Platform on May 18, 2020

April 27, 2020

Biogen Prices $3.0 Billion of Senior Unsecured Notes

April 22, 2020

Biogen Reports Q1 2020 Revenues of $3.5 Billion

April 20, 2020

Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics

April 16, 2020

Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank

April 8, 2020

Biogen to Report First Quarter 2020 Financial Results April 22, 2020

April 2, 2020

Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study

March 30, 2020

Biogen to Webcast Encore Aducanumab Presentation From Virtual AAT-AD/PD Meeting on April 2, 2020

March 18, 2020

Biogen Statement: Business Update Regarding COVID-19

March 16, 2020

Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World

February 27, 2020

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

February 24, 2020

Biogen to Present at the Cowen 40th Annual Health Care Conference

January 30, 2020

Biogen Reports Full Year 2019 Revenues of $14.4 Billion

January 13, 2020

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.

December 18, 2019

Biogen to Report Fourth Quarter and Year-End 2019 Financial Results January 30, 2020

December 17, 2019

Biogen to Present at the 38th Annual J.P. Morgan Healthcare Conference

December 13, 2019

Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy

December 3, 2019

Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)

November 22, 2019

Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)

November 21, 2019

Biogen to Present at the Evercore ISI 2nd Annual HealthCONx Conference

November 21, 2019

Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder

November 6, 2019

Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

November 4, 2019

Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019

October 30, 2019

Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

October 22, 2019

Biogen Reports Q3 2019 Revenues of $3.6 Billion

October 22, 2019

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

October 21, 2019

Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week

October 2, 2019

Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders

October 1, 2019

Biogen Announces Leadership Update

September 23, 2019

Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding

September 18, 2019

Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

September 17, 2019

Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

September 12, 2019

New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

September 11, 2019

Biogen to Report Third Quarter 2019 Financials October 22,2019

September 11, 2019

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

July 30, 2019

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

July 23, 2019

Biogen Q2 2019 Revenues Increased 8% to $3.6 Billion

July 1, 2019

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

June 19, 2019

Biogen to Report Second Quarter 2019 Financial Results July 23, 2019

June 11, 2019

Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019

June 7, 2019

Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

June 5, 2019

Biogen Announces Webcast of Annual Meeting of Stockholders

May 30, 2019

New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

May 21, 2019

Biogen to Present at Bernstein’s 35th Annual Strategic Decisions Conference

May 20, 2019

Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation

May 15, 2019

Biogen to Host Investor Webcast to Discuss ALS Portfolio on June 5, 2019

May 14, 2019

Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

May 7, 2019

Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS

May 6, 2019

Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)

May 1, 2019

Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)

May 1, 2019

Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases

April 30, 2019

Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy

April 29, 2019

Biogen Announces Three New Nominees for Election to Board of Directors

April 24, 2019

Biogen Q1 2019 Revenues Increased 11% to $3.5 Billion

April 12, 2019

Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference

March 27, 2019

Biogen to Present at the Stifel First Annual CNS Day

March 21, 2019

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease

March 13, 2019

Biogen to Report First Quarter 2019 Financial Results April 24, 2019

March 12, 2019

Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm

March 5, 2019

Biogen to Present at the Cowen 39th Annual Health Care Conference

March 4, 2019

Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology

February 28, 2019

Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy

February 25, 2019

Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis

January 29, 2019

Biogen Reports Record Revenues for Both the Full Year and Q4 2018, $13.5 Billion and $3.5 Billion, Respectively

January 4, 2019

Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions

January 4, 2019

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

January 3, 2019

First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis

December 17, 2018

Biogen to Present at the 37th Annual J.P. Morgan Healthcare Conference

December 17, 2018

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

December 10, 2018

Biogen to Report Fourth Quarter and Year-End 2018 Financial Results January 29, 2019

December 6, 2018

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data

November 29, 2018

International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product

November 26, 2018

Biogen to Present at the Evercore ISI HealthConX

November 19, 2018

Biogen To Host Investor Webcast On Its Multiple Sclerosis Portfolio On December 12, 2018

October 26, 2018

Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)

October 25, 2018

Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

October 23, 2018

Biogen Q3 2018 Revenues Increased 12% to $3.4 Billion

October 23, 2018

UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

October 18, 2018

Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

October 17, 2018

IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union

October 11, 2018

Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis

October 6, 2018

New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy

October 4, 2018

Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease Meeting on October 25-26, 2018

October 3, 2018

Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)

October 2, 2018

Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care

September 18, 2018

Biogen to Report Third Quarter 2018 Financial Results October 23, 2018

September 4, 2018

Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction

August 28, 2018

Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

July 25, 2018

Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018

July 25, 2018

Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018

July 24, 2018

Biogen Q2 2018 Revenues Increase 9% to $3.4 Billion

July 18, 2018

Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)

July 5, 2018

Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months

April 24, 2018

Biogen Reports Quarterly Revenues of $3.1 Billion

March 15, 2018

Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting

March 15, 2018

Biogen to Present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting

March 15, 2018

Biogen to Present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting

March 12, 2018

New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)

March 12, 2018

Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia

March 2, 2018

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

February 28, 2018

Biogen to Present at the Cowen and Company 38th Annual Health Care Conference

February 14, 2018

The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy

February 7, 2018

Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke

February 5, 2018

Biogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference

January 25, 2018

Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively

January 4, 2018

Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing

January 4, 2018

Biogen Foundation Commits $10 Million to STEM Education in Cambridge and Somerville

December 20, 2017

Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018

December 19, 2017

Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy

December 18, 2017

Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference

December 7, 2017

Biogen to Present at the Guggenheim 5th Annual Healthcare Conference

December 4, 2017

Biogen Appoints Mark Hernon as SVP, Chief Information Officer

November 27, 2017

Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis

November 21, 2017

Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer

November 20, 2017

Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference

November 2, 2017

Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation

November 2, 2017

Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

November 1, 2017

The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy

October 30, 2017

Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference

October 27, 2017

Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product

October 24, 2017

Biogen Reports Quarterly Revenues of $3.1 Billion

October 24, 2017

Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG

October 23, 2017

Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab

October 5, 2017

Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy

September 26, 2017

Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017

September 25, 2017

Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area

September 12, 2017

Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical

September 6, 2017

Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference

August 28, 2017

Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

August 24, 2017

IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union

July 31, 2017

Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences

July 25, 2017

Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance

July 24, 2017

Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations

July 14, 2017

Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)

July 10, 2017

Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs

June 29, 2017

New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity

June 28, 2017

Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs

June 23, 2017

Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use

June 20, 2017

Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017

June 20, 2017

Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer

June 14, 2017

Real World Data Being Presented at EULAR 2017 Demonstrate Acceptance and Confirm Sustainability of Effectiveness, Safety and Adherence among Patients Switching To BENEPALI® (Etanercept Biosimilar of Biogen) from Reference Etanercept

June 14, 2017

Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations

June 13, 2017

Biogen Announces Management Change

June 1, 2017

SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy

May 31, 2017

Biogen Announces Webcast of Virtual Annual Meeting of Stockholders

May 17, 2017

Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference

May 15, 2017

Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke

April 25, 2017

Biogen Reports First Quarter 2017 Revenues of $2.8 Billion

April 24, 2017

Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy

April 21, 2017

Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

April 18, 2017

Biogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress

April 13, 2017

Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb

March 28, 2017

Biogen to Present Data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases

March 27, 2017

Biogen to Report First Quarter 2017 Financial Results on April 25, 2017

March 16, 2017

Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development

February 28, 2017

Biogen to Present at the Cowen & Company 37th Annual Health Care Conference

February 15, 2017

Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference

February 7, 2017

Biogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference

February 1, 2017

Biogen Completes Separation of Global Hemophilia Business, Bioverativ

January 26, 2017

Biogen Reports 2016 Revenues of $11.4 Billion

January 17, 2017

Biogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017

January 17, 2017

Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis

January 17, 2017

Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement

January 13, 2017

New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy

January 12, 2017

Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock

December 23, 2016

U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy

December 22, 2016

Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement

December 22, 2016

Biogen Announces that Bioverativ will Host an Investor Day on January 6, 2017

December 21, 2016

Biogen and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

December 21, 2016

Biogen to Report Fourth Quarter and Year End 2016 Financial Results on January 26, 2017

December 20, 2016

Biogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock

December 20, 2016

Biogen to Present at the 35th Annual J.P. Morgan Healthcare Conference

December 19, 2016

Biogen Names Michel Vounatsos Chief Executive Officer

December 8, 2016

Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting

November 7, 2016

Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy

October 28, 2016

Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA

October 27, 2016

Biogen to Present at the 25th Annual Credit Suisse Healthcare Conference

October 26, 2016

Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion

October 8, 2016

New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy

September 26, 2016

Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy

September 15, 2016

New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Daclizumab) and Support Long-Term Safety Profile

September 14, 2016

Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016

September 14, 2016

New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting

September 8, 2016

Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio

September 1, 2016

Biogen to Present at the Morgan Stanley Global Healthcare Conference

September 1, 2016

Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation

August 31, 2016

Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab

August 9, 2016

Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company

August 1, 2016

Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy

July 21, 2016

Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion

July 18, 2016

Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress

July 17, 2016

SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency

July 5, 2016

Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis

June 21, 2016

Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology

June 20, 2016

Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016

June 9, 2016

New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio

June 7, 2016

Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis

June 1, 2016

Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program

May 31, 2016

Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy

May 30, 2016

FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union

May 27, 2016

Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis

May 19, 2016

Biogen Announces Webcast of Virtual Annual Meeting of Stockholders

May 16, 2016

Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs

May 13, 2016

Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B

May 3, 2016

Biogen Announces Intent to Spin off Its Hemophilia Business

April 29, 2016

Adam Koppel, Executive Vice President, Strategy and Business Development, to Return to Bain Capital

April 29, 2016

Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis

April 27, 2016

Biogen Appoints Michael Ehlers Executive Vice President, Research and Development

April 21, 2016

Biogen Reports First Quarter 2016 Revenues of $2.7 Billion

April 20, 2016

Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action

April 18, 2016

TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness

April 14, 2016

Biogen Joins in Celebration of World Hemophilia Day

April 12, 2016

Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients

April 1, 2016

FLIXABI®, an Infliximab Biosimilar Candidate Referencing Remicade®, Receives Positive CHMP Opinion

March 30, 2016

Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer

March 28, 2016

Biogen to Present at the Goldman Sachs Alzheimer’s Symposium

March 21, 2016

Biogen to Report First Quarter 2016 Financial Results on April 21, 2016

February 29, 2016

Biogen to Present at the Cowen and Company 36th Annual Health Care Conference

February 26, 2016

Sobi and Biogen Receive Positive Opinion from CHMP for Alprolix® (rFIXFc) for the Treatment of Hemophilia B

February 8, 2016

Biogen Joins Pioneering Target Validation Collaboration

February 4, 2016

Biogen to Present at the Leerink Partners 5th Annual Global Healthcare Conference

January 27, 2016

Biogen 2015 Revenues Increase 11% to $10.8 Billion

January 16, 2016

BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union

December 21, 2015

Biogen to Report Fourth Quarter and Year End 2015 Financial Results on January 27, 2016

December 18, 2015

Biogen to Present at the 34th Annual J.P. Morgan Healthcare Conference

November 24, 2015

Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A

November 20, 2015

Biogen Announces Benepali™ (Etanercept) is the First Biosimilar of Enbrel® to Receive a Positive Opinion from CHMP

November 11, 2015

Steven Holtzman to Retire from Biogen

October 21, 2015

Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS

October 21, 2015

Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance

October 12, 2015

Hemophilia Therapy from Largest Multi-Year Donation Now Available to Patients in Developing World

October 9, 2015

Biogen Announces Departure of Tony Kingsley

October 8, 2015

Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS

October 7, 2015

New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients

October 5, 2015

Biogen Announces Webcast of Investor R&D Day

October 1, 2015

Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, Including New TECFIDERA® Data Demonstrating Importance of Early Treatment

September 25, 2015

Biogen and Sobi Receive Positive Opinion from CHMP for ELOCTA™ (rFVIIIFc) for the Treatment of Hemophilia A

September 22, 2015

Biogen to Report Third Quarter 2015 Financial Results on October 21, 2015

September 11, 2015

Biogen Prices $6.0 Billion of Senior Unsecured Notes

September 10, 2015

CORRECTING and REPLACING Biogen to Present at Bank of America Merrill Lynch Global Healthcare Conference London

September 9, 2015

Biogen Licenses Mitsubishi Tanabe Pharma’s Phase 2 Molecule for Autoimmune Diseases

September 8, 2015

Biogen to Present at the Morgan Stanley Global Healthcare Conference

September 2, 2015

USPTO Dismisses Inter Partes Review Petition of Biogen’s Patent 514 for TECFIDERA® (Dimethyl Fumarate)

August 18, 2015

Biogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influence in ALS

August 17, 2015

Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B

August 10, 2015

Extension Study Data Supporting Long-Term Safety and Efficacy of Eloctate® Published in Haemophilia

July 27, 2015

Biogen Enters Collaboration with the Parkinson’s Institute and Clinical Center

July 24, 2015

Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion

July 22, 2015

Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015

July 10, 2015

Douglas Williams to Leave Biogen for Biotechnology Start-Up

July 6, 2015

Biogen to Report Second Quarter 2015 Financial Results on July 24, 2015

July 2, 2015

Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology

June 26, 2015

Biogen and Sobi Announce European Medicines Agency Validates ALPROLIX® (rFIXFc) Marketing Authorization Application

June 23, 2015

Biogen Achieves Carbon Neutrality

June 18, 2015

New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use

June 10, 2015

Biogen and Samsung Bioepis Announce New Data for Three Anti-TNF Biosimilar Development Candidates at EULAR 2015 Congress

May 28, 2015

Biogen 2015 Annual Shareholder Meeting Webcast

May 20, 2015

Biogen to Present at Bernstein’s 31st Annual Strategic Decisions Conference

May 13, 2015

Biogen to Present at the 2015 UBS Global Healthcare Conference

May 13, 2015

Biogen Names Matt Griffiths as Chief Information Officer

May 7, 2015

Biogen Announces $5 Billion Share Repurchase Program

May 7, 2015

Biogen to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

April 29, 2015

FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS

April 28, 2015

Biogen to Present at the 40th Annual Deutsche Bank Health Care Conference

April 24, 2015

Biogen Reports First Quarter 2015 Revenues of $2.6 Billion

April 21, 2015

PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients

April 21, 2015

International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction

April 20, 2015

TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients

April 14, 2015

Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

April 7, 2015

Biogen Data at AAN Annual Meeting Underscore Commitment to Advancing Patient Care in Neurology

April 1, 2015

Biogen to Report First Quarter 2015 Financial Results on April 24, 2015

March 27, 2015

European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS

March 23, 2015

Biogen Idec Becomes Biogen

March 20, 2015

Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference

February 27, 2015

Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX® Pediatric Study

February 23, 2015

Biogen Idec to Present at the Cowen and Company 35th Annual Healthcare Conference

February 19, 2015

Biogen Idec, Columbia University and HudsonAlpha Institute Identify New ALS Gene and Signaling Pathways

January 29, 2015

Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion

January 29, 2015

Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop Gene Therapies for Hemophilia

January 11, 2015

Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals

January 9, 2015

Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research

January 8, 2015

Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis

December 23, 2014

Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 28, 2015

December 3, 2014

Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting

November 19, 2014

Biogen Idec to Present at the 2014 Deutsche Bank BioFEST Conference

October 31, 2014

Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review

October 23, 2014

Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases

October 22, 2014

Biogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5 Billion

October 15, 2014

Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals

October 8, 2014

CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014

September 23, 2014

Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index

September 23, 2014

Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy

September 12, 2014

Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)

September 11, 2014

PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients

September 11, 2014

New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients

September 10, 2014

New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms

September 3, 2014

Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care

September 2, 2014

Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014

August 26, 2014

Biogen Idec in Panel at the Citi 9th Annual Biotech Conference

August 26, 2014

Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub

August 21, 2014

Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions

August 15, 2014

Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis

July 23, 2014

PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis

July 23, 2014

Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year

July 16, 2014

Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS)

June 30, 2014

Biogen Idec to Report Second Quarter 2014 Financial Results on July 23, 2014

June 16, 2014

Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis

June 6, 2014

FDA Approves Biogen Idec’s ELOCTATE™, First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children

May 30, 2014

Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses

May 28, 2014

Biogen Idec 2014 Annual Shareholder Meeting Webcast

May 28, 2014

Biogen Idec Announces Official Partnership with Sailing Sclerosis’ “Oceans of Hope” to Globally Change Perceptions of MS

May 23, 2014

CHMP Adopts Positive Opinion for PLEGRIDY™ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union

May 21, 2014

Biogen Idec to Present at the Sanford Bernstein 30th Annual Strategic Decisions Conference

May 12, 2014

Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine

May 12, 2014

Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World

May 8, 2014

Biogen Idec to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

May 1, 2014

New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients

April 30, 2014

Biogen Idec to Present at the Deutsche Bank 39th Annual Healthcare Conference

April 30, 2014

New Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity

April 29, 2014

Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting

April 23, 2014

Biogen Idec First Quarter 2014 Revenues Reach $2.1 Billion Driven by Continued Strength of MS Franchise

April 14, 2014

Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting

April 10, 2014

Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer

April 10, 2014

Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Investigational Therapy Eloctate™ (rFVIIIFc) for Hemophilia A

March 31, 2014

Biogen Idec to Report First Quarter 2014 Financial Results on April 23, 2014

March 28, 2014

FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart

March 21, 2014

Health Canada Approves Biogen Idec’s Long-Acting ALPROLIX™ Therapy for Hemophilia B

March 18, 2014

Biogen Idec Receives Notification of PDUFA Date Extension for Plegridy™ (Peginterferon Beta-1a)

March 5, 2014

Eisai and Biogen Idec Enter Collaboration to Develop and Commercialize Alzheimer’s Disease Treatments

February 25, 2014

Biogen Idec to Present at the Cowen & Company 34th Annual Health Care Conference

February 18, 2014

Biogen Idec to Present at the 2014 RBC Capital Markets’ Healthcare Conference

February 15, 2014

William D. Young To Retire From Biogen Idec’s Board of Directors

February 3, 2014

TECFIDERA® (Dimethyl Fumarate) Approved in the European Union as a First-Line Oral Treatment for Multiple Sclerosis

January 29, 2014

Biogen Idec 2013 Total Revenues Increase 26 Percent to $6.9 Billion

January 15, 2014

Biogen Idec to Report Fourth Quarter and Year-End 2013 Financial Results on January 29, 2014

January 9, 2014

BIOGEN IDEC AND SANGAMO BIOSCIENCES ANNOUNCE GLOBAL COLLABORATION TO DEVELOP TREATMENTS FOR HEMOGLOBINOPATHIES

January 7, 2014

Biogen Idec to Present at the 32nd Annual J.P. Morgan Healthcare Conference

January 2, 2014

Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

December 17, 2013

Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe

December 9, 2013

New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX™ and ELOCTATE™ Across Multiple Hemophilia Populations

December 4, 2013

The New England Journal of Medicine Publishes Pivotal Data Demonstrating Prophylactic Infusions of ALPROLIX™ Effectively Controlled Bleeding in Hemophilia B Patients

December 3, 2013

Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting

December 2, 2013

Biogen Idec Receives Notification from FDA of PDUFA Date Extension for ALPROLIX™

November 25, 2013

Biogen Idec to Present at the 2013 Deutsche Bank BioFEST

November 22, 2013

CHMP Determines Dimethyl Fumarate in TECFIDERA® to be a New Active Substance in the European Union

November 13, 2013

Leading Hematology Journal Publishes Pivotal ELOCTATE™ Data that Demonstrated Efficacy and Safety of Investigational Long-Lasting Therapy for Hemophilia A

November 5, 2013

Biogen Idec to Present at the Credit Suisse Healthcare Conference

October 28, 2013

Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance

October 7, 2013

Biogen Idec to Report Third Quarter 2013 Financial Results on October 28, 2013

October 4, 2013

New TECFIDERA® (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients

October 3, 2013

New TYSABRI® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity

October 2, 2013

Free Genetic Testing Initiative to be Available Nationally at Hemophilia Treatment Centers

October 1, 2013

New Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY™ (Peginterferon Beta-1a)

September 24, 2013

Biogen Idec Becomes First U.S.-Based Biotech Named to Dow Jones Sustainability World Index

September 23, 2013

Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS

September 20, 2013

Biogen Idec Employees Participate in Third Annual “Care Deeply Volunteer Day”

September 9, 2013

Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders

September 4, 2013

Biogen Idec Foundation Awards $250,000 Grant to Citizen Schools to Invest in Science Education in Massachusetts and North Carolina

September 3, 2013

Biogen Idec to Present at the Stifel Nicolaus 2013 Global Healthcare Conference

August 29, 2013

Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference

July 25, 2013

Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter 2013

July 19, 2013

US and EU Regulatory Authorities Accept PLEGRIDY™ (peginterferon beta-1a) Marketing Applications for Review

July 4, 2013

Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ELOCTATE™

July 3, 2013

Biogen Idec to Report Second Quarter 2013 Financial Results on July 25, 2013

July 2, 2013

Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ALPROLIX™

June 24, 2013

Biogen Idec Showcases Commitment to Advancing Hemophilia Treatment and Care at ISTH Congress

June 4, 2013

Biogen Idec 2013 Annual Shareholder Meeting Webcast

May 29, 2013

Biogen Idec Reinforces Commitment to MS Community on 5th Annual World MS Day

May 28, 2013

Biogen Idec to Present at the Jefferies 2013 Global Healthcare Conference

May 23, 2013

Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer

May 22, 2013

Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference

May 21, 2013

Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis

May 16, 2013

Biogen Idec Foundation Awards $250,000 to East End House to Develop Genetics Education Program

May 13, 2013

FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A

April 25, 2013

Biogen Idec Total Revenues Increased 10% to $1.4 Billion in First Quarter 2013

April 10, 2013

Biogen Idec to Report First Quarter 2013 Financial Results on April 25, 2013

April 4, 2013

The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Sclerosis

April 2, 2013

Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®

March 22, 2013

CHMP Issues Positive Opinion for TECFIDERA™ (Dimethyl Fumarate) as a First-Line Treatment for Multiple Sclerosis in the European Union

March 20, 2013

Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY™ (Peginterferon Beta-1a) Presented at AAN Meeting

March 19, 2013

US Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA™ (Dimethyl Fumarate)

March 18, 2013

ADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status

March 18, 2013

New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status

March 12, 2013

Biogen Idec Submits Application to FDA for First Long-Lasting Factor VIII Therapy for Hemophilia A

March 6, 2013

Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN Annual Meeting

March 4, 2013

FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B

February 27, 2013

Biogen Idec to Present at the Cowen and Company 33rd Annual Healthcare Conference

February 20, 2013

Biogen Idec to Present at the 2013 RBC Capital Markets Global Healthcare Conference

February 19, 2013

Biogen Idec to Present at the Citi 2013 Global Healthcare Conference

February 15, 2013

Cambridge Science Festival Announces Statewide Year-Round Science Outreach Initiative: Biogen Idec Foundation Science on the Street

February 8, 2013

New Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and B

February 6, 2013

Biogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for Upfront Cash and Contingent Payments

January 28, 2013

Biogen Idec 2012 Revenue Increases 9% to $5.5 Billion

January 24, 2013

Biogen Idec Announces Positive Top-Line Results from Phase 3 Study of Peginterferon Beta-1a in Multiple Sclerosis

January 16, 2013

Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in anti-JCV Antibody Negative Patients with MS

January 14, 2013

Biogen Idec to Report Fourth Quarter & Year End 2012 Financial Results on January 28, 2013

January 4, 2013

Biogen Idec Submits Application to FDA for First Long-Lasting Factor IX Therapy for Hemophilia B

January 3, 2013

Biogen Idec Reports Top-Line Results from Phase 3 Trial Investigating Dexpramipexole in People with Amyotrophic Lateral Sclerosis (ALS)

January 2, 2013

Biogen Idec to Present at the 31st Annual J.P. Morgan Healthcare Conference

December 20, 2012

Biogen Idec Forms First-of-Its-Kind Research Consortium to Identify ALS Drug Targets

December 12, 2012

Biogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle Park Facilities

November 29, 2012

Biogen Idec Opens New RTP Facility

November 26, 2012

Biogen Idec to Present at the DB Access BioFEST Conference

November 7, 2012

Biogen Idec to Present at the Credit Suisse 2012 Annual Healthcare Conference

October 31, 2012

Biogen Idec and Sobi Announce Positive Top-Line Results from Phase 3 Study Investigating Long-Lasting Recombinant Factor VIII Fc Fusion Protein in Hemophilia A

October 25, 2012

Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter

October 18, 2012

Biogen Idec Receives Notification of PDUFA Date Extension

October 12, 2012

New Data from Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect for Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis

October 11, 2012

TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS

October 10, 2012

Biogen Idec’s Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS

October 4, 2012

Biogen Idec to Report Third Quarter 2012 Financial Results on October 25, 2012

September 26, 2012

BIOGEN IDEC AND SOBI ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING LONG-LASTING RECOMBINANT FACTOR IX FC FUSION PROTEIN IN HEMOPHILIA B

September 19, 2012

The New England Journal of Medicine Publishes Pivotal Data Demonstrating Efficacy and Safety of Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis

September 14, 2012

Biogen Idec Employees Participate in 80 Volunteer Projects in 22 Countries as Part of Annual “Care Deeply Volunteer Day”

September 12, 2012

Biogen Idec Foundation Awards $1 Million to Museum of Science to Support Stem Education in Massachusetts

September 10, 2012

Biogen Idec Sells BENLYSTA Royalty Rights to DRI Capital Managed Fund

September 4, 2012

Biogen Idec to Present at the Morgan Stanley Global Healthcare Unplugged Conference

August 29, 2012

Biogen Idec to Present at the Stifel Nicolaus Healthcare Conference 2012

August 17, 2012

Biogen Idec Foundation Donates $100,000 to Launch STEM Education Collaboration with Teach for America

July 24, 2012

CORRECTING and REPLACING Biogen Idec Increases Revenue 18% to $1.4 Billion in the Second Quarter

July 17, 2012

Biogen Idec Announces Collaboration with Leading Research Institutions to Sequence Genomes of Patients with ALS

July 5, 2012

Biogen Idec to Report Second Quarter 2012 Financial Results on July 24, 2012

July 5, 2012

Biogen Idec and Sobi Initiate Global Clinical Trials of Long-Lasting Hemophilia A and B Product Candidates in Children

June 29, 2012

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Myotonic Dystrophy

June 12, 2012

Biogen Idec to Highlight Innovative Pipeline and Commercial Strategy

June 5, 2012

Biogen Idec Announces Webcast of 2012 Analyst Day

June 1, 2012

Biogen Idec 2012 Annual Shareholders Meeting Webcast

May 30, 2012

Biogen Idec Continues Support for MS Community with Worldwide Celebrations on Fourth Annual World MS Day

May 17, 2012

New Analysis of Risk Stratification for TYSABRI® Published in New England Journal of Medicine

May 14, 2012

New AVONEX® Dosing Innovations for People with Multiple Sclerosis Now Available in US

May 9, 2012

US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review

May 2, 2012

Biogen Idec to Present at the Deutsche Bank 37th Annual Healthcare Conference

May 1, 2012

Biogen Idec Increases Revenue 7% to $1.3 Billion in the First Quarter

April 26, 2012

New TYSABRI Data Presented at 64th Annual AAN Meeting Highlight Biogen Idec & Elan Commitment to Improving Outcomes in Multiple Sclerosis

April 24, 2012

Positive Results from Phase 3 CONFIRM Clinical Trial Show Efficacy and Safety of Oral BG-12 in Multiple Sclerosis

April 20, 2012

New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s Commitment to Deliver Promising Therapies for Unmet Needs in Neurodegenerative Diseases

April 9, 2012

Biogen Idec to Report First Quarter 2012 Financial Results on May 1, 2012

March 6, 2012

Biogen Idec to Present at the Barclays 2012 Global Healthcare Conference

February 28, 2012

Biogen Idec to Present at the Cowen & Company 32nd Annual Healthcare Conference

February 28, 2012

Biogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis

February 28, 2012

FDA Approves AVONEX® PEN™ and Dose Titration Regimen

February 27, 2012

Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis

February 22, 2012

Biogen Idec to Present at the Citi 2012 Global Healthcare Conference

February 14, 2012

Biogen Idec to Acquire Stromedix

February 8, 2012

Biogen Idec to Present at the Leerink Swann Global Healthcare Conference

January 31, 2012

Biogen Idec Surpasses $5 Billion in 2011 Annual Revenue

January 30, 2012

Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources

January 26, 2012

ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis

January 20, 2012

FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor

January 13, 2012

Biogen Idec to Report Fourth Quarter & Year End 2011 Financial Results on January 31, 2012

January 9, 2012

Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan Healthcare Conference

January 4, 2012

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy

January 3, 2012

Biogen Idec to Present at the 30th Annual J.P. Morgan Healthcare Conference

December 28, 2011

Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

December 5, 2011

Samsung and Biogen Idec Announce Joint Venture to Develop, Manufacture and Market Biosimilars

November 30, 2011

Biogen Idec to Present at the 2011 Deutsche Bank BioFEST

October 28, 2011

Biogen Idec Reports Third Quarter 2011 Results

October 27, 2011

Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases

October 26, 2011

Biogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis

October 22, 2011

Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select Phase 2B Trial at ECTRIMS/ACTRIMS

October 21, 2011

Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial

October 20, 2011

Biogen Idec and Elan Receive Notification of PDUFA Date Extension

October 19, 2011

Data about Early Use and Long-Term Benefit of TYSABRI Presented at 5th Joint Triennial Congress of ECTRIMS and ACTRIMS

October 12, 2011

Data Presented at the 5th Joint Triennial Congress of ECTRIMS and ACTRIMS Demonstrates Biogen Idec’s Novel Science and Commitment to MS Patients

October 11, 2011

Biogen Idec to Report Third Quarter 2011 Financial Results on October 28, 2011

September 30, 2011

More Than 1,000 Biogen Idec Employees across the Globe Help Patients, Communities in First “Care Deeply Volunteer Day”

September 29, 2011

Biogen Idec Promotes Tony Kingsley to Run Global Commercial Operations

September 14, 2011

Biogen Idec to Present at the UBS Global Life Sciences Conference

September 8, 2011

Biogen Idec to Present at the Morgan Stanley 2011 Global Healthcare Unplugged Conference

September 6, 2011

Biogen Idec Fully Acquires Biogen Dompé Joint Ventures

August 31, 2011

Biogen Idec Announces Webcast of Hemophilia R&D Roundtable

August 30, 2011

Biogen Idec to Present at the Stifel Nicolaus 2011 Healthcare Conference

August 9, 2011

Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis

July 27, 2011

Biogen Idec Strengthens MS ActiveSource® for People with Multiple Sclerosis

July 26, 2011

Biogen Idec Reports Second Quarter 2011 Results

July 26, 2011

Biogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting Recombinant Factor VIII Therapy at International Society on Thrombosis and Haemostasis Meeting

July 25, 2011

Biogen Idec Receives Conditional Approval in the European Union for FAMPYRA® to Improve Walking in Adults with Multiple Sclerosis

July 7, 2011

Biogen Idec to Report Second Quarter 2011 Financial Results on July 26, 2011

July 3, 2011

Biogen Idec Researchers Identify Novel Approach for Promoting Remyelination and Inhibiting Autoimmune Activation as Potential Therapeutic Option for Treatment of Multiple Sclerosis

June 22, 2011

European Commission Approves Inclusion of Anti-JC Virus Antibody Status as a PML Risk Factor in TYSABRI Labeling

June 7, 2011

CORRECTING and REPLACING Biogen Idec Receives Approval in the European Union for AVONEX® PEN™

June 6, 2011

CORRECTING and REPLACING Biogen Idec Reports Positive Data from AVONEX Dose Titration Study at 2011 Annual Meeting of the Consortium of Multiple Sclerosis Centers

June 1, 2011

Biogen Idec to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference

June 1, 2011

Biogen Idec to Present at the Jefferies 2011 Global Healthcare Conference

May 26, 2011

Biogen Idec 2011 Annual Shareholder Meeting Webcast

May 26, 2011

2,700 Students in Greater Boston and North Carolina to Benefit from Biogen Idec Foundation Science Education Grants

May 25, 2011

Biogen Idec Celebrates World MS Day

May 24, 2011

Biogen Idec Launches Women in MS Educational Initiative

May 20, 2011

European Medicines Agency’s Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorisation Application for FAMPYRA

May 16, 2011

Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS

May 9, 2011

Biogen Idec and Swedish Orphan Biovitrum Receive Opinion from EMA on Pediatric Plan for Long-Lasting Hemophilia B Therapy

May 4, 2011

Biogen Idec to Present at the Bank of America Merrill Lynch 2011 Healthcare Conference

April 27, 2011

Biogen Idec to Present at the Deutsche Bank 36th Annual Healthcare Conference

April 21, 2011

Biogen Idec Reports First Quarter 2011 Results

April 19, 2011

FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis

April 19, 2011

Biogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on AVONEX PEN

April 18, 2011

CHMP Recommends Updating TYSABRI Labeling with anti-JC Virus Antibody Status as a Third Factor to Further Stratify Risk of PML

April 14, 2011

CORRECTING and REPLACING Biogen Idec to Report First Quarter 2011 Financial Results on April 21, 2011 Before Market Open, Conference Call at 7:00 am ET

April 11, 2011

Biogen Idec’s Ongoing Dedication to People Living with MS Showcased in Data Presented at the 63rd Annual Meeting of the American Academy of Neurology

April 11, 2011

Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in Multiple Sclerosis

March 31, 2011

Biogen Idec and Knopp Biosciences Announce Enrollment of the First Patient in a Global Phase III Study of Dexpramipexole for ALS

March 3, 2011

Biogen Idec to Present at the Cowen 31st Annual Healthcare Conference

February 24, 2011

Biogen Idec to Present at the Citi 2011 Global Healthcare Conference

February 9, 2011

Biogen Idec to Present at the ISI Annual Conference

February 1, 2011

CORRECTING and REPLACING Biogen Idec Reports Full Year and Fourth Quarter 2010 Results

January 28, 2011

FDA Approves Rituxan for First-Line Maintenance Use in Follicular Lymphoma

January 21, 2011

Biogen Idec Receives Negative Opinion from the CHMP on FAMPYRA

January 14, 2011

Biogen Idec to Report Fourth Quarter and Year End 2010 Financial Results on February 1, 2011

January 11, 2011

Biogen Idec Provides Business Update at Investor Meeting

January 5, 2011

Biogen Idec to Present at the 29th Annual J.P. Morgan Healthcare Conference

January 5, 2011

Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development

December 22, 2010

Biogen Idec and Elan Submit Applications to Update TYSABRI Labeling That May Help Stratify Risk of PML with Anti-JC Virus Antibody Status

December 20, 2010

Biogen Idec and Neurimmune Announce Agreement on Three Neurodegenerative Disease Programs

December 17, 2010

Amanda Freitag of Chopped and Iron Chef America Teams up with Multiple Sclerosis Nutritionist to Create Nutrition Resource for People with MS

December 9, 2010

Biogen Idec to Present at the 2010 Deutsche Bank BioFEST

December 7, 2010

Biogen Idec Awards Clinical Fellowship Program Grants to Support Education and Research for the Treatment of Multiple Sclerosis

December 6, 2010

Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Lasting Recombinant Factor VIII Fc Fusion Protein

December 5, 2010

Phase III Study Showed Rituxan® for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in People with Asymptomatic Follicular Lymphoma, a Common Type of Blood Cancer

November 22, 2010

Biogen Idec Announces Webcast of Neurodegeneration & Repair R&D Roundtable

November 10, 2010

Biogen Idec to Present at the Lazard Capital Markets 7th Annual Healthcare Conference

November 3, 2010

Biogen Idec and Cardiokine Dissolve Collaboration for Lixivaptan

November 3, 2010

Biogen Idec Announces Framework for Growth Through Increased Focus and Efficiency

October 26, 2010

Biogen Idec Reports Third Quarter 2010 Results

October 21, 2010

Biogen Idec and Genentech Announce Restructuring of anti-CD20 Collaboration Agreement

October 16, 2010

Data Further Supporting Anti-JC Virus Antibody Assay Presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

October 15, 2010

Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients

October 6, 2010

Biogen Idec Showcases Global, Multiple Sclerosis Leadership with More Than 45 Data Presentations at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

October 4, 2010

Biogen Idec to Report Third Quarter 2010 Financial Results on October 26, 2010

September 22, 2010

Biogen Idec Makes Statement About U.S. FDA Approval of Gilenya™

September 21, 2010

Biogen Idec Announces Webcast of Hemophilia R&D Roundtable

September 16, 2010

Celebrity Trainer and Leading Neurologist Team up to Create New Wellness Resource for People with Multiple Sclerosis

September 15, 2010

Biogen Idec to Present at the 2010 UBS Global Life Sciences Conference

September 9, 2010

Biogen Idec to Present at the Stifel Nicolaus 2010 Healthcare Conference

September 8, 2010

Biogen Idec to Present at the 2010 Morgan Stanley Global Healthcare Unplugged Conference

August 24, 2010

Preliminary Data in Support of Investigational Anti-JCV Antibody Assay Published in the Annals of Neurology

August 18, 2010

Biogen Idec and Knopp Neurosciences Announce License Agreement for Late-Stage ALS Drug Candidate

July 20, 2010

Biogen Idec Reports Second Quarter 2010 Results

July 9, 2010

Biogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial

June 30, 2010

Biogen Idec Names George Scangos Chief Executive Officer

June 28, 2010

Biogen Idec to Report Second Quarter 2010 Financial Results on July 20, 2010

June 15, 2010

Biogen Idec Announces Enrollment of First Patient in Phase II BG-12 Combination Trial in Multiple Sclerosis

June 7, 2010

Biogen Idec Provides Update on CEO Search and Management Changes

June 4, 2010

Biogen Idec 2010 Annual Shareholder Meeting Webcast

May 25, 2010

Biogen Idec Globally Commemorates Annual World MS Day

May 24, 2010

Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapsing-Remitting Multiple Sclerosis

May 21, 2010

Biogen Idec to Present at the 2010 Citi Investment Research Global Healthcare Conference

May 20, 2010

Phase III Study Showed First-Line Maintenance Use of Rituxan® Improved the Likelihood of People with Follicular Lymphoma Living without Their Disease Worsening

May 19, 2010

Roche and Biogen Idec Announce Their Decision to Discontinue the ocrelizumab Clinical Development Programme in Patients with Rheumatoid Arthritis

May 6, 2010

Biogen Idec to Present at the Bank of America Merrill Lynch 2010 Healthcare Conference

April 20, 2010

Biogen Idec Reports First Quarter 2010 Results TYSABRI® Revenues Increase 32% Year over Year

April 13, 2010

Large Body of Data on TYSABRI® to Be Presented at Annual Meeting of the American Academy of Neurology

April 7, 2010

Biogen Idec to Report First Quarter 2010 Financial Results on April 20, 2010

April 5, 2010

Biogen Idec Strengthens Position as a Leader in Neurology with 38 Data Presentations at 62nd Annual Meeting of the American Academy of Neurology

March 25, 2010

Biogen Idec and Elan Enroll First Patient in Large, Well-Controlled Head-to-Head Study of Multiple Sclerosis Treatments

March 22, 2010

Biogen Idec Appoints Eric Rowinsky and Stephen Sherwin to Board of Directors Pursuant to Agreement with Icahn Partners

March 19, 2010

Biogen Idec to Present at the Barclays Capital 2010 Global Healthcare Conference

March 5, 2010

Biogen Idec to Present at the Cowen and Company 30th Annual Health Care Conference

February 18, 2010

FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia

February 18, 2010

Biogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement

February 9, 2010

Biogen Idec Reports Full Year and Fourth Quarter 2009 Results

February 8, 2010

Multiple Sclerosis Experts Join Biogen Idec’s Research and Development Team

January 28, 2010

Biogen Idec Receives Notice of Intention to Nominate Directors at 2010 Meeting of Shareholders

January 25, 2010

Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Acting Hemophilia B Therapy

January 23, 2010

Biogen Idec Issues Statement on U.S. Approval of AMPYRA™ (dalfampridine)

January 15, 2010

Biogen Idec to Report Fourth Quarter and Full Year 2009 Financial Results on February 9, 2010

January 12, 2010

Biogen Idec Submits Application in Europe for the Approval of Fampridine-PR Tablets to Improve Walking Ability in People with Multiple Sclerosis

January 11, 2010

World-Renowned Yogi Baron Baptiste Unveils New Program to Help People with Multiple Sclerosis

January 7, 2010

Biogen Idec Adds Senior Leadership to Commercial and Medical Operations

January 5, 2010

Biogen Idec to Present at the 28th Annual J.P. Morgan Healthcare Conference

January 4, 2010

Biogen Idec Names Caroline Dorsa to Board of Directors

January 4, 2010

Biogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire

January 4, 2010

Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted 2010: A View from the Top

December 15, 2009

Biogen Idec Stands Ready to Close Its $17.50 All-Cash Tender Offer for Facet Biotech

December 11, 2009

Biogen Idec Stands Ready to Close Its $17.50 Per Share All-Cash Tender Offer for Facet Biotech

December 10, 2009

William D. Young to Become Chairman of Biogen Idec

December 10, 2009

Biogen Idec to Present at the 2009 Deutsche Bank Biotech Boston Confab

December 3, 2009

Biogen Idec Increases Offer to Acquire Facet Biotech to $17.50 Per Share in Cash; Sends Letter to Facet Biotech Stockholders Describing Its Best-and-Final Offer

November 10, 2009

CORRECTING and REPLACING Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference

November 10, 2009

Biogen Idec to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

October 27, 2009

Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn’s Disease

October 20, 2009

Biogen Idec Reports Third Quarter 2009 Results

October 19, 2009

Elan to Highlight Tysabri Data in Crohn’s Disease at the American College of Gastroenterology Annual Scientific Meeting

October 19, 2009

Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial

October 16, 2009

Biogen Idec Extends Offer to Acquire Facet Biotech Corporation for $14.50 Per Share in Cash

October 7, 2009

Biogen Idec to Report Third Quarter 2009 Financial Results on October 20, 2009

September 21, 2009

Biogen Idec Commences Tender Offer for Facet Biotech

September 18, 2009

Biogen Idec to Present at the UBS Global Life Sciences Conference

September 11, 2009

Data Supporting Unique Efficacy of TYSABRI Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

September 10, 2009

Biogen Idec to Present at the Morgan Stanley Global Healthcare Unplugged Conference

September 9, 2009

Biogen Idec Foundation Announces $1 Million Gift to North Carolina Biotechnology Center

September 8, 2009

Biogen Idec Reiterates Proposal to Acquire All Outstanding Shares of Facet for $14.50 Per Share in Cash

September 4, 2009

Biogen Idec Announces Proposal to Acquire All Outstanding Shares of Facet for $14.50 per Share in Cash

September 2, 2009

Biogen Idec to Present at the Thomas Weisel Partners Healthcare Conference

September 2, 2009

Biogen Idec Showcases More Than 70 Data Presentations at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

July 16, 2009

Phillip A. Sharp to Retire from Biogen Idec Board

July 8, 2009

Biogen Idec Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis

July 2, 2009

Biogen Idec to Report Second Quarter 2009 Financial Results on July 16, 2009

July 1, 2009

Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.

June 22, 2009

Biogen Idec Announces First Patient Enrolled in the Global Phase III Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis

June 16, 2009

Biogen Idec Announces Conclusion of Arbitration with Genentech

June 9, 2009

Biogen Idec Announces Preliminary Tabulation of Stockholder Vote by Independent Inspector of Elections

June 9, 2009

Biogen Idec to Present at the Goldman Sachs 30th Annual Healthcare Conference

June 4, 2009

Biogen Idec Announces Preliminary Results of Stockholder Vote

May 31, 2009

Subset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn’s Disease Patients with Prior Exposure or Inadequate Response to Anti-TNFα Therapy

May 27, 2009

Biogen Idec Joins with the Global MS Community to Mark World MS Day

May 26, 2009

Biogen Idec Sends Letter to Stockholders

May 24, 2009

Biogen Idec Comments on Proxy Advisory Firms’ Reports

May 19, 2009

Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia

May 14, 2009

Biogen Idec to Present at the Deutsche Bank 34th Annual Health Care Conference

April 30, 2009

First Ten-Year Follow-Up Shows That Treatment with AVONEX® Leads to Long-Term Benefits in Early Multiple Sclerosis Patients

April 28, 2009

MRI Data Showing TYSABRI® Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology

April 27, 2009

Biogen Idec Board Recommends Shareholders Elect Directors with Record of Success in Enhancing the Value of the Company

April 16, 2009

Biogen Idec Reports First Quarter 2009 Results

April 16, 2009

Biogen Idec Receives Approval for TYSABRI® High Titer Production

April 15, 2009

Biogen Idec Showcases Leading Multiple Sclerosis Franchise and Pipeline at the 61st Annual Meeting of the American Academy of Neurology

April 7, 2009

Biogen Idec to Report First Quarter 2009 Financial Results on April 16, 2009

March 30, 2009

Biogen Idec to Present at the 4(th) Annual Citi Biotech Day

March 30, 2009

Biogen Idec Names Robert Hamm Chief Operating Officer

March 25, 2009

Biogen Idec Highlights Progress and Breadth of Pipeline Programs at R&D Day

March 18, 2009

Biogen Idec Announces March 25 Webcast of Research & Development Day

March 12, 2009

Biogen Idec Announces Head of Research and Development Dr. Cecil B. Pickett to Retire

March 11, 2009

Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint

March 10, 2009

Biogen Idec to Present at the Cowen & Company 29th Annual Healthcare Conference

February 23, 2009

Biogen Idec Names Michael Lytton Executive Vice President of Business Development

February 9, 2009

MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology

February 6, 2009

Biogen Idec Reports Full Year and Fourth Quarter 2008 Results

February 6, 2009

Biogen Idec Receives Shareholder Proposal

January 9, 2009

Biogen Idec to Report Fourth Quarter and Full Year 2008 Financial Results on February 6, 2009

January 6, 2009

Biogen Idec to Present at the 27th Annual J.P. Morgan Healthcare Conference

January 5, 2009

Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

December 6, 2008

Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer

November 14, 2008

Biogen Idec to Present at the Lazard Capital Markets Fifth Annual Life Sciences Conference

November 7, 2008

Biogen Idec to Present at the Credit Suisse 2008 Healthcare Conference

October 30, 2008

Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule

October 28, 2008

Biogen Idec to Present at the Oppenheimer 19th Annual Healthcare Conference

October 27, 2008

Rituxan Data in Patients with Rheumatoid Arthritis to Be Presented at the American College of Rheumatology Annual Scientific Meeting

October 23, 2008

Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis

October 21, 2008

Biogen Idec Reports Third Quarter 2008 Results

October 9, 2008

Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis

October 7, 2008

Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia

September 30, 2008

Biogen Idec to Report Third Quarter 2008 Financial Results on October 21, 2008

September 23, 2008

Biogen Idec Announces Webcast of Presentation at the UBS Global Life Sciences Conference

September 19, 2008

TYSABRI(R) Demonstrates Sustained Improvement in Functional Outcomes in Multiple Sclerosis Patients According to New Post-Hoc Analysis

September 18, 2008

New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life

September 18, 2008

Biogen Idec Features Data on AVONEX(R) and TYSABRI(R) and Showcases the Company's Multiple Sclerosis Development Pipeline at the World Congress On Treatment and Research in Multiple Sclerosis

September 5, 2008

Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology

September 4, 2008

Biogen Idec to Present at the 3rd Annual CITI Biotech Day

August 26, 2008

Biogen Idec to Present at the Thomas Weisel Partners Healthcare Conference

August 21, 2008

Biogen Idec Initiates Phase III Clinical Trial for ADENTRI(R) in Acute Decompensated Heart Failure Patients with Renal Insufficiency

July 31, 2008

Biogen Idec and Elan Will Host a Conference Call For the Investment Community

July 24, 2008

Biogen Idec Names Brian S. Posner to Board of Directors

July 22, 2008

Biogen Idec Reports Second Quarter 2008 Results

July 22, 2008

Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis

July 9, 2008

Biogen Idec Announces Certified Stockholder Vote Results, Confirming Election of All Four of the Board's Director Nominees

July 7, 2008

Biogen Idec to Report Second Quarter 2008 Financial Results on July 22, 2008

June 19, 2008

Biogen Idec Stockholders Elect Company's Board Nominees

June 11, 2008

Proxy Governance Endorses All Four Biogen Idec Director Nominees

June 10, 2008

RiskMetrics and Glass Lewis Endorse All Four Biogen Idec Director Nominees

May 29, 2008

Biogen Idec Names Hans Peter Hasler Chief Operating Officer

May 19, 2008

Biogen Idec Celebrates 30 Years of Transforming Discovery into Care

May 8, 2008

Biogen Idec Commences Mailing of Proxy Materials to Shareholders

April 29, 2008

Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus

April 23, 2008

Biogen Idec Reports First Quarter 2008 Results

April 17, 2008

Biogen Idec Announces Slate of Directors for Annual Meeting of Shareholders

April 16, 2008

Data Presented at the 60th Annual Meeting of the American Academy of Neurology Offers Additional Support for Plasma Exchange as a Potential Tool to Accelerate TYSABRI(R) Removal

April 15, 2008

Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology

April 15, 2008

Biogen Idec Announces Multiple Sclerosis Franchise and Pipeline Presentations at the 60th Annual Meeting of the American Academy of Neurology

April 14, 2008

Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis

April 1, 2008

Biogen Idec to Report First Quarter 2008 Financial Results on April 23, 2008

March 24, 2008

Researchers Report Neublastin Virtually Restores Complete Long-Term Sensory Motor Function in Preclinical Studies

March 10, 2008

Biogen Idec to Present at the Cowen & Company 28th Annual Healthcare Conference

February 29, 2008

Biogen Idec Prices $1.0 Billion Senior Unsecured Notes Offering

February 14, 2008

Biogen Idec and Cardiokine Initiate Phase III Clinical Trial for Lixivaptan in Congestive Heart Failure Patients with Hyponatremia

February 6, 2008

Biogen Idec Reports Full Year and Fourth Quarter 2007 Results

January 31, 2008

Biogen Idec Announces Webcast of Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

January 28, 2008

Biogen Idec Receives Director Nomination Proposal

January 23, 2008

Biogen Idec to Present at the Wachovia 2008 Healthcare Conference

January 15, 2008

Biogen Idec to Report Fourth Quarter and Full Year 2007 Financial Results on February 6, 2008

January 14, 2008

FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease

January 10, 2008

Biogen Idec Announces Appointment of Nancy L. Leaming to Board of Directors

January 8, 2008

Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech

January 7, 2008

Biogen Idec Provides Business Update at Investor Meeting

January 7, 2008

Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI(R) in Patients with Multiple Sclerosis

January 3, 2008

Biogen Idec to Present at the 26th Annual JPMorgan Healthcare Conference